Background Non-small cell lung cancer (NSCLC) imposes a substantial burden on patients,
health care systems and society due to increasing incidence and poor survival rates. In …

Precision oncology is not an illusion, nor is it the magic bullet that will eradicate all cancers.
Precision oncology is simply another weapon in our growing armament against cancer …

Introduction Lung cancer, the most prevalent malignant cancer in the world, remains a
serious threat to public health. Recently, a large number of studies have shown that an …

Lung cancer remains the leading cause of cancer-related death and economic burden
worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved …

Background Over the last 15 years, a paradigm shift in oncology has led to the approval of
dozens of targeted oral anti-cancer medications (OAMs), which have become the standard …

During these last years, there have been an increased number of new drugs for non-small
cell lung cancer (NSCLC), with a growing financial effect on patients and society. The …

Objective To review and assess the quality of the available evidence on the cost-
effectiveness of erlotinib in the first-line treatment of advanced non-small cell lung cancer …

Objective To assess the cost-effectiveness of erlotinib versus supportive care (placebo)
overall and within a predefined rash subgroup in elderly patients with advanced non-small …

Background Evolving practices in non-small cell lung cancer (NSCLC) therapy inevitably
affect health care budgets, especially through the introduction of targeted therapies. This …

Résumé Le cancer bronchique reste le cancer le plus meurtrier, dont la cause la plus
fréquente est le tabagisme, cause par ailleurs évitable, contrairement à d'autres types de …